Azacitidine
"Azacitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
| Descriptor ID |
D001374
|
| MeSH Number(s) |
D02.145.150 D03.383.742.680.245.217 D13.570.685.245.217 D13.570.800.286.300
|
| Concept/Terms |
Azacitidine- Azacitidine
- 5-Azacytidine
- 5 Azacytidine
- Azacytidine
|
Below are MeSH descriptors whose meaning is more general than "Azacitidine".
Below are MeSH descriptors whose meaning is more specific than "Azacitidine".
This graph shows the total number of publications written about "Azacitidine" by people in this website by year, and whether "Azacitidine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2006 | 0 | 2 | 2 | | 2008 | 1 | 3 | 4 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 3 | 4 | | 2012 | 0 | 2 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 2 | 0 | 2 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 4 | 5 | | 2019 | 0 | 4 | 4 | | 2020 | 1 | 3 | 4 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 7 | 7 | | 2023 | 1 | 2 | 3 | | 2024 | 4 | 0 | 4 | | 2025 | 1 | 1 | 2 | | 2026 | 2 | 4 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Azacitidine" by people in Profiles.
-
Wang ES, Erba H, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano ND, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Oct 01; 148(14):1775-1788.
-
Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood Cancer J. 2026 Jun 29; 16(1).
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
-
Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA. Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy. Haematologica. 2026 Sep 01; 111(9):2957-2965.
-
Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA. Tolerability and Outcomes With Serial Cycles of 28?Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. Am J Hematol. 2026 Apr; 101(4):728-735.
-
Lee ES, Tommer ER, Rothman PB, Middleton SV, Youmans DT, Cech TR. Single-molecule tracking of DNMT1 in living cells reveals its cell cycle dynamics and its redistribution upon drug treatment. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Islam N, Dale JL, Reuben JS, Sapiah K, Coates JW, Markson FR, Zhang J, Wu L, Gasparetto M, Stevens BM, Staggs SE, Showers WM, Ransom MR, Desai J, Kulkarni UV, Engel KL, Jordan CT, Boyiadzis M, Smith CA. Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine. JCO Clin Cancer Inform. 2025 12; 9:e2400308.
-
Khang A, Barmore A, Tseropoulos G, Bera K, Batan D, Anseth KS. Automated prediction of fibroblast phenotypes using mathematical descriptors of cellular features. Nat Commun. 2025 Mar 22; 16(1):2841.
-
Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Haematologica. 2024 12 01; 109(12):3918-3927.
-
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|